Johnson & Johnson ROA 2012-2026 | JNJ
Current and historical return on assets (ROA) values for Johnson & Johnson (JNJ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Johnson & Johnson ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $21.04B | $146.35B | 14.38% |
| 2025-12-31 | $26.80B | $194.77B | 13.76% |
| 2025-09-30 | $25.12B | $190.00B | 13.22% |
| 2025-06-30 | $22.66B | $186.36B | 12.16% |
| 2025-03-31 | $21.81B | $183.29B | 11.90% |
| 2024-12-31 | $14.07B | $177.86B | 7.91% |
| 2024-09-30 | $14.68B | $174.73B | 8.40% |
| 2024-06-30 | $38.02B | $171.67B | 22.15% |
| 2024-03-31 | $38.48B | $174.32B | 22.07% |
| 2023-12-31 | $35.15B | $180.32B | 19.49% |
| 2023-09-30 | $34.62B | $185.27B | 18.69% |
| 2023-06-30 | $13.05B | $187.54B | 6.96% |
| 2023-03-31 | $12.72B | $184.05B | 6.91% |
| 2022-12-31 | $17.94B | $179.65B | 9.99% |
| 2022-09-30 | $19.16B | $178.31B | 10.74% |
| 2022-06-30 | $18.37B | $179.33B | 10.24% |
| 2022-03-31 | $19.83B | $179.01B | 11.08% |
| 2021-12-31 | $20.88B | $177.56B | 11.76% |
| 2021-09-30 | $17.88B | $175.78B | 10.17% |
| 2021-06-30 | $17.77B | $173.65B | 10.23% |
| 2021-03-31 | $15.12B | $169.13B | 8.94% |
| 2020-12-31 | $14.71B | $164.75B | 8.93% |
| 2020-09-30 | $16.99B | $160.46B | 10.59% |
| 2020-06-30 | $15.19B | $156.66B | 9.69% |
| 2020-03-31 | $17.17B | $155.85B | 11.01% |
| 2019-12-31 | $15.12B | $154.60B | 9.78% |
| 2019-09-30 | $14.15B | $153.41B | 9.22% |
| 2019-06-30 | $16.33B | $153.45B | 10.64% |
| 2019-03-31 | $14.68B | $153.51B | 9.56% |
| 2018-12-31 | $15.30B | $155.16B | 9.86% |
| 2018-09-30 | $1.54B | $156.25B | 0.99% |
| 2018-06-30 | $1.37B | $156.24B | 0.88% |
| 2018-03-31 | $1.25B | $155.60B | 0.80% |
| 2017-12-31 | $1.30B | $152.67B | 0.85% |
| 2017-09-30 | $15.83B | $148.65B | 10.65% |
| 2017-06-30 | $16.34B | $144.83B | 11.28% |
| 2017-03-31 | $16.51B | $141.58B | 11.66% |
| 2016-12-31 | $16.54B | $139.41B | 11.86% |
| 2016-09-30 | $15.94B | $137.46B | 11.60% |
| 2016-06-30 | $15.03B | $135.68B | 11.08% |
| 2016-03-31 | $15.55B | $133.74B | 11.62% |
| 2015-12-31 | $15.41B | $131.83B | 11.69% |
| 2015-09-30 | $14.72B | $131.06B | 11.23% |
| 2015-06-30 | $16.11B | $130.77B | 12.32% |
| 2015-03-31 | $15.92B | $131.56B | 12.10% |
| 2014-12-31 | $16.32B | $132.75B | 12.30% |
| 2014-09-30 | $17.32B | $133.33B | 12.99% |
| 2014-06-30 | $15.55B | $132.04B | 11.78% |
| 2014-03-31 | $15.06B | $129.32B | 11.65% |
| 2013-12-31 | $13.83B | $126.37B | 10.94% |
| 2013-09-30 | $12.88B | $123.54B | 10.43% |
| 2013-06-30 | $12.87B | $121.54B | 10.59% |
| 2013-03-31 | $10.44B | $119.40B | 8.74% |
| 2012-12-31 | $10.85B | $118.06B | 9.19% |
| 2012-09-30 | $8.50B | $116.14B | 7.32% |
| 2012-06-30 | $8.74B | $114.35B | 7.64% |
| 2012-03-31 | $10.11B | $113.44B | 8.91% |
| 2011-12-31 | $9.67B | $111.43B | 8.68% |
| 2011-09-30 | $11.40B | $108.75B | 10.48% |
| 2011-06-30 | $11.61B | $105.36B | 11.02% |
| 2011-03-31 | $12.28B | $100.40B | 12.23% |
| 2010-12-31 | $13.33B | $96.72B | 13.79% |
| 2010-09-30 | $13.60B | $94.67B | 14.36% |
| 2010-06-30 | $13.53B | $93.00B | 14.54% |
| 2010-03-31 | $13.29B | $91.78B | 14.47% |
| 2009-12-31 | $12.27B | $89.95B | 13.64% |
| 2009-09-30 | $12.77B | $87.50B | 14.60% |
| 2009-06-30 | $12.74B | $86.54B | 14.72% |
| 2009-03-31 | $12.86B | $86.71B | 14.83% |
| 2008-12-31 | $12.95B | $86.69B | 14.94% |
| 2008-09-30 | $12.61B | $85.70B | 14.71% |
| 2008-06-30 | $11.85B | $83.43B | 14.20% |
| 2008-03-31 | $11.60B | $80.07B | 14.49% |
| 2007-12-31 | $10.58B | $76.84B | 13.76% |
| 2007-09-30 | $10.37B | $74.24B | 13.97% |
| 2007-06-30 | $10.58B | $69.89B | 15.14% |
| 2007-03-31 | $10.32B | $66.46B | 15.53% |
| 2006-12-31 | $11.05B | $63.73B | 17.34% |
| 2006-09-30 | $10.98B | $60.81B | 18.06% |
| 2006-06-30 | $10.76B | $59.64B | 18.04% |
| 2006-03-31 | $10.53B | $58.03B | 18.14% |
| 2005-12-31 | $10.06B | $56.11B | 17.93% |
| 2005-09-30 | $8.85B | $54.72B | 16.18% |
| 2005-06-30 | $8.66B | $53.60B | 16.15% |
| 2005-03-31 | $8.53B | $52.51B | 16.24% |
| 2004-12-31 | $8.18B | $51.11B | 16.00% |
| 2004-09-30 | $9.14B | $49.85B | 18.33% |
| 2004-06-30 | $8.87B | $48.49B | 18.29% |
| 2004-03-31 | $7.62B | $47.36B | 16.09% |
| 2003-12-31 | $7.20B | $45.64B | 15.77% |
| 2003-09-30 | $6.74B | $43.72B | 15.41% |
| 2003-06-30 | $6.39B | $41.72B | 15.32% |
| 2003-03-31 | $6.83B | $39.89B | 17.13% |
| 2002-12-31 | $6.60B | $38.97B | 16.93% |
| 2002-09-30 | $6.32B | $38.45B | 16.43% |
| 2002-06-30 | $6.12B | $38.05B | 16.09% |
| 2002-03-31 | $5.95B | $37.49B | 15.87% |
| 2001-12-31 | $5.67B | $35.88B | 15.80% |
| 2001-09-30 | $5.45B | $34.82B | 15.66% |
| 2001-06-30 | $5.25B | $33.25B | 15.78% |
| 2001-03-31 | $5.13B | $31.80B | 16.13% |
| 2000-12-31 | $4.89B | $31.32B | 15.61% |
| 2000-09-30 | $4.75B | $30.05B | 15.82% |
| 2000-06-30 | $4.54B | $29.39B | 15.46% |
| 2000-03-31 | $4.34B | $28.59B | 15.19% |
| 1999-12-31 | $4.17B | $27.79B | 15.00% |
| 1999-09-30 | $3.52B | $27.05B | 13.00% |
| 1999-06-30 | $3.37B | $25.85B | 13.03% |
| 1999-03-31 | $3.22B | $24.65B | 13.07% |
| 1998-12-31 | $3.00B | $23.44B | 12.81% |
| 1998-09-30 | $3.53B | $22.25B | 15.87% |
| 1998-06-30 | $3.42B | $21.84B | 15.67% |
| 1998-03-31 | $3.31B | $21.51B | 15.40% |
| 1997-12-31 | $3.30B | $21.19B | 15.59% |
| 1997-09-30 | $3.23B | $20.83B | 15.50% |
| 1997-06-30 | $3.12B | $20.39B | 15.32% |
| 1997-03-31 | $3.01B | $19.96B | 15.06% |
| 1996-12-31 | $2.89B | $19.54B | 14.77% |
| 1996-09-30 | $2.80B | $19.01B | 14.71% |
| 1996-06-30 | $2.67B | $18.45B | 14.46% |
| 1996-03-31 | $2.54B | $17.97B | 14.13% |
| 1995-12-31 | $2.40B | $17.40B | 13.81% |
| 1995-09-30 | $2.32B | $16.85B | 13.75% |
| 1995-06-30 | $2.22B | $16.13B | 13.75% |
| 1995-03-31 | $2.12B | $15.15B | 13.97% |
| 1994-12-31 | $2.01B | $14.19B | 14.13% |
| 1994-09-30 | $1.96B | $13.34B | 14.72% |
| 1994-06-30 | $1.89B | $12.73B | 14.87% |
| 1994-03-31 | $1.83B | $12.42B | 14.72% |
| 1993-12-31 | $1.79B | $12.21B | 14.64% |
| 1993-09-30 | $1.76B | $12.12B | 14.52% |
| 1993-06-30 | $1.72B | $11.97B | 14.36% |
| 1993-03-31 | $1.68B | $11.72B | 14.30% |
| 1992-12-31 | $1.65B | $11.35B | 14.53% |
| 1992-09-30 | $1.62B | $11.01B | 14.68% |
| 1992-06-30 | $1.57B | $10.52B | 14.88% |
| 1992-03-31 | $1.52B | $10.06B | 15.09% |
| 1991-12-31 | $1.46B | $9.77B | 14.95% |
| 1991-09-30 | $1.42B | $9.52B | 14.90% |
| 1991-06-30 | $1.37B | $9.45B | 14.51% |
| 1991-03-31 | $1.32B | $9.38B | 14.04% |
| 1990-12-31 | $1.14B | $9.22B | 12.40% |
| 1990-09-30 | $1.11B | $8.82B | 12.63% |
| 1990-06-30 | $1.07B | $8.34B | 12.78% |
| 1990-03-31 | $1.01B | $7.94B | 12.70% |
| 1989-12-31 | $1.08B | $7.62B | 14.19% |
| 1989-09-30 | $1.06B | $7.42B | 14.32% |
| 1989-06-30 | $1.04B | $7.25B | 14.32% |
| 1989-03-31 | $1.01B | $7.12B | 14.22% |
| 1988-12-31 | $0.97B | $7.02B | 13.88% |
| 1988-09-30 | $0.95B | $6.88B | 13.86% |
| 1988-06-30 | $0.92B | $6.83B | 13.51% |
| 1988-03-31 | $0.88B | $6.69B | 13.10% |
| 1987-12-31 | $0.83B | $6.50B | 12.81% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |